Search
Pyrvinium
go.drugbank.com/drugs/DB06816ApprovedInvestigationalWithdrawnSeveral forms of pyrvinium have been prepared with variable counter anions, such as halides, tosylate, triflate and pamoate. Pyrvinum's anti-cancer properties are currently under investigation.
Cacodylic acid
go.drugbank.com/drugs/DB02994ExperimentalCategories: Compounds used in a research, industrial, or household settingHalothane
go.drugbank.com/drugs/DB01159ApprovedVet approvedWithdrawnA nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly.
CX-051869
go.drugbank.com/drugs/DB31656ApprovedIt is the active ingredient of the 2025-2026 formulation of Moderna's Spikevax vaccine.[L40074] … CX-051869 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage LP.8.1.
Diiodohydroxyquinoline
go.drugbank.com/drugs/DB09115ApprovedDiiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown.
Molsidomine
go.drugbank.com/drugs/DB09282ApprovedWithdrawnMolsidomine is an orally active, long-acting vasodilator, which belongs to the class of medications known as syndnones.
Products: Nesidom 16 mg - Retardtabletten, Molsidolat 4 mg TablettenTricaprylin
go.drugbank.com/drugs/DB12176InvestigationalTricaprilin has been used in trials studying the supportive care and treatment of Alzheimer's Disease.
Categories: Compounds used in a research, industrial, or household settingDenopamine
go.drugbank.com/drugs/DB21277ExperimentalDenopamine has a monoisotopic molecular weight of 317.16 Da.
Categories: Compounds used in a research, industrial, or household settingCyclandelate
go.drugbank.com/drugs/DB04838ApprovedWithdrawnCyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.
Sunvozertinib
go.drugbank.com/drugs/DB18925Investigational[A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor